These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

380 related items for PubMed ID: 23106476

  • 21. Relation of resistin to proprotein convertase subtilisin-kexin type 9 levels in coronary artery disease patients with different nutritional status.
    Li S, Xu RX, Zhang Y, Guo YL, Zhu CG, Liu G, Dong Q, Li JJ.
    J Endocrinol Invest; 2015 Dec; 38(12):1291-9. PubMed ID: 26003826
    [Abstract] [Full Text] [Related]

  • 22. Proprotein Convertase Subtilisin Kexin 9 (PCSK9) and nonHDL particles rise during normal pregnancy and differ by BMI.
    Wild RA, Weedin E, Cox K, Zhao YD, Wrenn DS, Lopez D, Wooten CJ, Melendez QM, Myers D, Hansen KR.
    J Clin Lipidol; 2022 Dec; 16(4):483-490. PubMed ID: 35717446
    [Abstract] [Full Text] [Related]

  • 23. Relation of plasma PCSK9 levels to lipoprotein subfractions in patients with stable coronary artery disease.
    Xu RX, Li S, Zhang Y, Li XL, Guo YL, Zhu CG, Li JJ.
    Lipids Health Dis; 2014 Dec 11; 13():188. PubMed ID: 25496400
    [Abstract] [Full Text] [Related]

  • 24. Proprotein convertase subtilisin/kexin 9 inhibitors: an emerging lipid-lowering therapy?
    Dragan S, Serban MC, Banach M.
    J Cardiovasc Pharmacol Ther; 2015 Mar 11; 20(2):157-68. PubMed ID: 24938457
    [Abstract] [Full Text] [Related]

  • 25. Plasma proprotein convertase subtilisin-kexin type 9 does not change during 24h insulin infusion in healthy subjects and type 2 diabetic patients.
    Kappelle PJ, Lambert G, Dullaart RP.
    Atherosclerosis; 2011 Feb 11; 214(2):432-5. PubMed ID: 21122860
    [Abstract] [Full Text] [Related]

  • 26. Function and distribution of circulating human PCSK9 expressed extrahepatically in transgenic mice.
    Luo Y, Warren L, Xia D, Jensen H, Sand T, Petras S, Qin W, Miller KS, Hawkins J.
    J Lipid Res; 2009 Aug 11; 50(8):1581-8. PubMed ID: 19060325
    [Abstract] [Full Text] [Related]

  • 27. Association of serum proprotein convertase Subtilisin/Kexin Type 9 (PCSK9) level with thyroid function disorders.
    Yildirim AM, Koca AO, Beyan E, Dogan O, Karakaya S, Aksoz Z, Ertuğrul DT.
    Eur Rev Med Pharmacol Sci; 2021 Sep 11; 25(17):5511-5517. PubMed ID: 34533801
    [Abstract] [Full Text] [Related]

  • 28. Plasma proprotein convertase subtilisin/kexin type 9: a marker of LDL apolipoprotein B-100 catabolism?
    Chan DC, Lambert G, Barrett PH, Rye KA, Ooi EM, Watts GF.
    Clin Chem; 2009 Nov 11; 55(11):2049-52. PubMed ID: 19713274
    [Abstract] [Full Text] [Related]

  • 29. Association of plasma small dense LDL cholesterol with PCSK9 levels in patients with angiographically proven coronary artery disease.
    Zhang Y, Xu RX, Li S, Zhu CG, Guo YL, Sun J, Li JJ.
    Nutr Metab Cardiovasc Dis; 2015 Apr 11; 25(4):426-33. PubMed ID: 25770756
    [Abstract] [Full Text] [Related]

  • 30. Plasma PCSK9 in nephrotic syndrome and in peritoneal dialysis: a cross-sectional study.
    Jin K, Park BS, Kim YW, Vaziri ND.
    Am J Kidney Dis; 2014 Apr 11; 63(4):584-9. PubMed ID: 24315769
    [Abstract] [Full Text] [Related]

  • 31. Hepatic overexpression of idol increases circulating protein convertase subtilisin/kexin type 9 in mice and hamsters via dual mechanisms: sterol regulatory element-binding protein 2 and low-density lipoprotein receptor-dependent pathways.
    Sasaki M, Terao Y, Ayaori M, Uto-Kondo H, Iizuka M, Yogo M, Hagisawa K, Takiguchi S, Yakushiji E, Nakaya K, Ogura M, Komatsu T, Ikewaki K.
    Arterioscler Thromb Vasc Biol; 2014 Jun 11; 34(6):1171-8. PubMed ID: 24675665
    [Abstract] [Full Text] [Related]

  • 32. Elevated PCSK9 levels in untreated patients with heterozygous or homozygous familial hypercholesterolemia and the response to high-dose statin therapy.
    Raal F, Panz V, Immelman A, Pilcher G.
    J Am Heart Assoc; 2013 Apr 24; 2(2):e000028. PubMed ID: 23537802
    [Abstract] [Full Text] [Related]

  • 33. AMG 145, a monoclonal antibody against PCSK9, facilitates achievement of national cholesterol education program-adult treatment panel III low-density lipoprotein cholesterol goals among high-risk patients: an analysis from the LAPLACE-TIMI 57 trial (LDL-C assessment with PCSK9 monoclonal antibody inhibition combined with statin thErapy-thrombolysis in myocardial infarction 57).
    Desai NR, Giugliano RP, Zhou J, Kohli P, Somaratne R, Hoffman E, Liu T, Scott R, Wasserman SM, Sabatine MS.
    J Am Coll Cardiol; 2014 Feb 11; 63(5):430-3. PubMed ID: 24161333
    [Abstract] [Full Text] [Related]

  • 34. Several genetic polymorphisms interact with overweight/obesity to influence serum lipid levels.
    Yin RX, Wu DF, Miao L, Aung LH, Cao XL, Yan TT, Long XJ, Liu WY, Zhang L, Li M.
    Cardiovasc Diabetol; 2012 Oct 08; 11():123. PubMed ID: 23039238
    [Abstract] [Full Text] [Related]

  • 35. Evidence from a randomized trial that simvastatin, but not ezetimibe, upregulates circulating PCSK9 levels.
    Berthold HK, Seidah NG, Benjannet S, Gouni-Berthold I.
    PLoS One; 2013 Oct 08; 8(3):e60095. PubMed ID: 23544125
    [Abstract] [Full Text] [Related]

  • 36. Serum proprotein convertase subtilisin kexin type 9 is correlated directly with serum LDL cholesterol.
    Alborn WE, Cao G, Careskey HE, Qian YW, Subramaniam DR, Davies J, Conner EM, Konrad RJ.
    Clin Chem; 2007 Oct 08; 53(10):1814-9. PubMed ID: 17702855
    [Abstract] [Full Text] [Related]

  • 37. A semi-automated mass spectrometric immunoassay coupled to selected reaction monitoring (MSIA-SRM) reveals novel relationships between circulating PCSK9 and metabolic phenotypes in patient cohorts.
    Gauthier MS, Pérusse JR, Awan Z, Bouchard A, Tessier S, Champagne J, Krastins B, Byram G, Chabot K, Garneau P, Rabasa-Lhoret R, Faubert D, Lopez MF, Seidah NG, Coulombe B.
    Methods; 2015 Jun 15; 81():66-73. PubMed ID: 25770357
    [Abstract] [Full Text] [Related]

  • 38. Plasma proprotein convertase subtilisin/kexin type 9 is associated with Lp(a) in type 2 diabetic patients.
    Nekaies Y, Baudin B, Kelbousi S, Sakly M, Attia N.
    J Diabetes Complications; 2015 Jun 15; 29(8):1165-70. PubMed ID: 26412029
    [Abstract] [Full Text] [Related]

  • 39. Influence of physiological changes in endogenous estrogen on circulating PCSK9 and LDL cholesterol.
    Ghosh M, Gälman C, Rudling M, Angelin B.
    J Lipid Res; 2015 Feb 15; 56(2):463-9. PubMed ID: 25535288
    [Abstract] [Full Text] [Related]

  • 40. Gene inactivation of proprotein convertase subtilisin/kexin type 9 reduces atherosclerosis in mice.
    Denis M, Marcinkiewicz J, Zaid A, Gauthier D, Poirier S, Lazure C, Seidah NG, Prat A.
    Circulation; 2012 Feb 21; 125(7):894-901. PubMed ID: 22261195
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.